Chemical industry in Japan

First-in-class oral OX2R agonist now available; U.S. launch due next month pending DEA scheduling; Phase 3 showed significant improvements across NT1 symptoms with a consistent safety profile.

Speech-to-text plus generative AI structures shop-floor voice logs into reusable digital assets, cutting work-analysis time by over 90% and enabling tacit-knowledge transfer.

Composite polyester-nylon raw yarn contains ≥93% recycled mass (raw-yarn basis); ARTIROSA CX fabrics to launch FW 2027 with 200,000 m initial sales target.

Pilot will collect post-consumer and post-industrial foam, chemically hydrolyse it to recover high-purity polyols and amines as drop-in feedstock, and assess commercial scale-up in Japan.

Vamikibart showed sustained vision gains and reduced macular thickness at 52 weeks in MEERKAT and SANDCAT; FDA has accepted the BLA with a decision due by July 2027.

Phase 3 data show sustained PASI90/PASI100 and IGA 0/1 responses to Week 112, durable itch improvement, and no new safety signals.

Independent Data Monitoring Committee advised stopping the trial for futility after an interim analysis; safety remained consistent and no new signals were seen.

Prototype film capacitor with a 150°C dielectric ran stably in an inverter; thermal simulation suggests heat-dissipation structure could be halved, aiding lighter air‑cooled units.

Long-acting cabotegravir + rilpivirine achieved superior viral suppression versus standard oral ART at six months when initiated in people with detectable HIV.

Yokohama technical center began cell therapy process development in July 2025 and has been awarded multiple exosome and T‑cell projects, including a program transferred from Milan.